Bundling Rapid Human Immunodeficiency Virus and Hepatitis C Virus Testing to Increase Receipt of Test Results

A Randomized Trial

Bibliographic Data

ID9104684
AuthorsJemima A Frimpong (0000-0002-7393-3085, The Johns Hopkins Carey Business School, Baltimore, MD, corresponding author), Karen Shiu-Yee (Mailman School of Public Health, Columbia University), Karen Shiu‐yee (0000-0002-2367-031X, Columbia University), Susan Tross (HIV Center for Clinical and Behavioral Studies Division of Gender, Sexuality, and Health New York State Psychiatric Institute and Columbia University), Thomas D’Aunno (NYU Wagner Graduate School of Public Service), David C Perlman (0000-0001-5674-025X, Icahn School of Medicine at Mount Sinai), Shiela M Strau (0000-0002-6911-6277, KES College), Shiela M Strauss (NYU Rory Meyers College of Nursing), Bruce R Schackman (0000-0002-1132-2932, Weill Cornell Medical College, New York, NY, corresponding author), Daniel J Feaster (0000-0002-6172-7460, University of Miami Miller School of Medicine, Miami, FL), Lisa R Metsch (0000-0001-5966-3982, Mailman School of Public Health, Columbia University)
Year2020
Volume58
Issue5
Pages445-452
Publication date2020-05-01
Peer ReviewedYes
Open AccessNo
TypeARTICLE
VenueMedical Care (JOURNAL)
Journal identifiersISSN: 0025-7079 • E-ISSN: 1537-1948
PublisherOvid Technologies (Wolters Kluwer Health) (PUBLISHER)
DOI10.1097/mlr.0000000000001311
PMID32040038
OpenAlexW3005858358
LanguageEN
Citations received1
References cited31

BACKGROUND: The overlapping human immunodeficiency virus (HIV) and hepatitis C virus (HCV) epidemics disproportionately affect people with substance use disorders. However, many people who use substances remain unaware of their infection(s). OBJECTIVE: The objective of this study was to examine the efficacy of an on-site bundled rapid HIV and HCV testing strategy in increasing receipt of both HIV and HCV test results. RESEARCH DESIGN: Two-armed randomized controlled trial in substance use disorder treatment programs (SUDTP) in New York City. Participants in the treatment arm were offered bundled rapid HIV and HCV tests with immediate results on-site. Participants in the control arm were offered the standard of care, that is, referrals to on-site or off-site laboratory-based HIV and HCV testing with delayed results. PARTICIPANTS: A total of 162 clients with unknown or negative HIV and HCV status. MEASURES: The primary outcome was the percentage of participants with self-reported receipt of HIV and HCV test results at 1-month postrandomization. RESULTS: Over half of participants were Hispanic (51.2%), with 25.3% being non-Hispanic black and 17.9% non-Hispanic white. Two thirds were male, and 54.9% reported injection as method of drug use. One hundred thirty-four participants (82.7%) completed the 1-month assessment. Participants in the treatment arm were more likely to report having received both test results than those in the control arm (69% vs. 19%, P<0.001). Seven participants in the treatment arm received a preliminary new HCV diagnosis, versus 1 in the control arm (P=0.029). CONCLUSION: Offering bundled rapid HIV and HCV testing with immediate results on-site in SUDTPs may increase awareness of HIV and HCV infection among people with substance use disorders

Hepatitis C · Hepatitis C virus · Human immunodeficiency virus (HIV) · Randomized controlled trial · Receipt · Virus · Hepatitis C virus research · HIV, Drug Use, Sexual Risk · HIV/AIDS Research and Interventions · Immunology · Internal Medicine · Medicine

Tools

Open DOIOpen Access